Biomedical subjects

K A Gallardo

Publications and source records attributed to K A Gallardo.

8 recordsLinked to original sources

PubMed2002

Nicotinic acetylcholine receptor-mediated release of [3H]norepinephrine from developing and adult rat hippocampus: direct and indirect mechanisms.

The primary role of nicotinic acetylcholine receptors in adult and developing brain is to modulate neurotransmission. Using in vitro neurotransmitter release, we have examined mechanisms underlying nicotine-induced [(3)H]norepinephrine release from developing and adult rat hippocampus. At birth, nicotine significantly stimulated hippocampal [(3)H]norepinephrine release with a monotonic increase in maximal drug effect over the first ten postnatal days. No developmental changes in agonist or antagonist potency were observed. Comparison of synaptosomal and slice preparations, as well as examination of the effects of tetrodotoxin, indicated that at least two nicotinic acetylcholine receptor populations regulated [(3)H]norepinephrine release from neonatal and adult hippocampus; one localized on noradrenergic terminals, the other on adjacent cells. To further characterize the indirect mechanism of nicotine action in the adult, we examined the effects of pharmacological blockade of various neurotransmitter systems that provide excitatory input to hippocampal noradrenergic terminals. Whereas glutamate and muscarinic receptor blockade was ineffective, the GABA-A receptor antagonists, bicuculline and picrotoxin, inhibited the indirect component of nicotine-mediated [(3)H]norepinephrine release. Furthermore, pentobarbital, an allosteric effector at GABA-A receptors, potentiated the effect of submaximal concentrations of nicotine. These findings are consistent with the hypothesis that nicotine-induced GABA release serves as an additional stimulus for [(3)H]norepinephrine secretion within rat hippocampus.

Animals↗

PubMed1999

The effect of nicotine on developing brain catecholamine systems.

Biochemical studies have confirmed that nicotinic acetylcholine receptor mRNA and protein are expressed early in the development of the fetal central nervous system. Perinatal administration of nicotine produces a broad spectrum of effects on brain development, including inhibition of DNA synthesis, altered ornithine decarboxylase activity, altered neurotransmitter function, and significant alterations in cortical morphogenesis. Catecholamine systems, both in the brain and in the periphery, are particularly sensitive to prenatal nicotine exposure. Acute and chronic nicotine administered to pregnant dams causes alterations in dopamine and its metabolites in male and female rat fetuses. These changes can persist into adulthood. Prenatal nicotine exposure also causes locomotor disturbances in pups, which can have long-lasting effects. The effect of nicotine on developing noradrenergic neurons is less clear. Some effects may include increases in noradrenergic neuronal activity in the pup and aberrant central release of norepinephrine in response to neonatal hypoxia after nicotine exposure in utero. Catecholamine neurons develop early in ontogeny, so nicotine induced alterations have the potential to induce permanent changes. Hence, more research is needed to get a clearer picture of the effect of nicotine on developing catecholamine systems. The affects of nicotine on catecholamine systems in the adult are discussed for comparison.

Animals↗

PubMed1998

Nicotine-stimulated release of [3H]norepinephrine from fetal rat locus coeruleus cells in culture.

Acute nicotine administration stimulated [3H]norepinephrine ([3H]NE) release from cultured fetal locus coeruleus (LC) cells. The effect was concentration dependent, with an EC50 of 0.9 microM, and was abolished by removal of calcium from, or addition of tetrodotoxin (500 nM) to, the assay buffer. Other nicotinic receptor agonists stimulated [3H]NE release, with the rank order of potency being (+)-epibatidine > (-)-nicotine > 1,1-dimethyl-4-phenylpiperazinium (DMPP). Whereas (-)-nicotine and (+/-)-epibatidine exhibited equal maximal responses, DMPP was a partial agonist and (-)-cytisine had no agonist activity. Nicotine-stimulated release of [3H]NE was blocked by nicotinic receptor antagonists, with an order of potency of mecamylamine > lobeline > cytisine > methyllycaconitine > dihydro-beta-erythroidine. The pharmacological profile of this nicotinic receptor is largely consistent with that described previously for an alpha4beta2 subunit combination, although discrepancies in the efficacies of agonists were observed. No additivity in NMDA- and nicotine-stimulated [3H]NE release was observed, suggesting a common signal transduction mechanism. However, the pharmacological characteristics of MK-801 blockade of nicotine-induced responses were not consistent with those of an NMDA receptor. We therefore conclude that nicotine directly releases [3H]NE from LC cells and does not act indirectly via activation of glutamate release.

Alkaloids↗

PubMed1998

Neonatal treatment with 192 IgG-saporin produces long-term forebrain cholinergic deficits and reduces dendritic branching and spine density of neocortical pyramidal neurons.

The role of basal forebrain-derived cholinergic afferents in the development of neocortex was studied in postnatal rats. Newborn rat pups received intraventricular injections of 192 IgG-saporin. Following survival periods ranging from 2 days to 6 months, the brains were processed to document the cholinergic lesion and to examine morphological consequences. Immunocytochemistry for choline acetyltransferase (ChAT) and in situ hybridization for ChAT mRNA demonstrate a loss of approximately 75% of the cholinergic neurons in the medial septum and nucleus of the diagonal band of Broca in the basal forebrain. In situ hybridization for glutamic acid decarboxylase mRNA reveals no loss of basal forebrain GABAergic neurons. Acetylcholinesterase histochemistry demonstrates a marked reduction of the cholinergic axons in neocortex. Cholinergic axons are reduced throughout the cortical layers; this reduction is more marked in medial than in lateral cortical areas. The thickness of neocortex is reduced by approximately 10%. Retrograde labeling of layer V cortico-collicular pyramidal cells reveals a reduction in cell body size and also a reduction in numbers of branches of apical dendrites. Spine densities on apical dendrites are reduced by approximately 20-25% in 192 IgG-saporin-treated cases; no change was detected in number of spines on basal dendrites. These results indicate a developmental or maintenance role for cholinergic afferents to cerebral cortical neurons.

Acetylcholinesterase↗

PubMed1991

Molecular forms of acetylcholinesterase in cerebral cortex and dorsal thalamus of developing rats.

Histochemical studies show that primary sensory regions of rat cerebral cortex and dorsal thalamus display transient patterns of intense acetylcholinesterase (AChE) activity during early postnatal development. Sucrose gradient fractionation techniques were used to determine the molecular forms of AChE in developing rat brain at the time of onset (postnatal day 5), during peak expression (days 10-11), and after decline (day 18) of the transient AChE expression. Tissue from auditory and visual regions of cortex and from dorsal thalamus at each age examined contained 10S and 4S forms of AChE, similar to the pattern observed in mature brain. The 10S form was almost totally membrane bound; the 4S form was largely soluble. Hemithalamic lesions reduce both forms of AChE in cortex. These data indicate that transiently expressed AChE does not represent a unique or unusual form of the enzyme.

Acetylcholinesterase↗

PubMed1991

Primary auditory cortex in the rat: transient expression of acetylcholinesterase activity in developing geniculocortical projections.

A characteristic pattern of acetylcholinesterase (AChE) activity is expressed transiently in primary auditory cortex (cortical area 41) of developing laboratory rats during early postnatal life. This AChE activity occurs as a dense plexus in cortical layer IV and the deep part of layer III. This transient band of AChE activity is first detected by histochemical techniques on postnatal day (P) 3, reaches peak intensity at approximately P8-10, and declines to form the adult pattern by P23. The ventral nucleus of the medial geniculate body of the thalamus also displays prominent, and transient, staining for AChE. This intense staining for AChE, found within neuronal somata and neuropil, is detected at the time of birth, reaches peak intensity around P8, and declines to adult levels by P16. The areal and laminar patterns of the transient band of AChE activity in temporal cortex correspond to the patterns of anterograde transneuronal labeling of geniculocortical terminals following injection of wheat germ agglutinin conjugated to horseradish peroxidase (WGA-HRP) into the inferior colliculus. Placement of lesions that include the medial geniculate nucleus or the geniculocortical axons results in a marked decrease in AChE staining in thalamorecipient layers of auditory cortex. Placement of lesions that include the medial globus pallidus reduce AChE staining of some axons in temporal cortex of developing rats, but the dense band of AChE in layers III and IV remains. Placement of lesions in the inferior colliculus in newborn animals results in marked decrease in AChE staining in cells of the ipsilateral ventral medial geniculate nucleus and in ipsilateral auditory cortex of developing pups. These data indicate that transiently expressed AChE activity is characteristic of geniculocortical neurons, including their somata in the medial geniculate body and their terminal axons in primary auditory cortex. This AChE activity is expressed early in postnatal development, probably during the time when thalamocortical axons are proliferating in cortical layer IV and forming synaptic contacts with cortical neurons.

Acetylcholinesterase↗

PubMed1990

Distribution of 'non-specific' cholinesterase histochemical staining in the dorsal thalamus: a comparative study in rodents.

Histochemical studies in rat dorsal thalamus demonstrate that 'non-specific' cholinesterase (ChE) enzyme activity is characteristic of neurons of the anterior dorsal (AD) and reuniens (Re) nuclei and in a cell group found as part of the central lateral (CL) and lateral dorsal (LD) nuclei. Extra-somatal ChE staining also is seen in the anterior ventral (AV) nucleus. Parallel histochemical studies in other rodents reveal slight ChE activity in neurons of the mouse AD and LD, but not in other thalamic nuclei. The dorsal thalami of hamsters, gerbils and guinea pigs show no detectable cellular staining of ChE, although low levels of extra-somatal ChE appear in AV and the internal medullary lamina. These data indicate that 'non-specific' cholinesterase activity is not found commonly in neurons of the dorsal thalamus and prominent ChE staining may be unique to the laboratory rat.

Animals↗

PubMed1990

Relationships between patterns of acetylcholinesterase activity and geniculocortical terminal fields in developing and mature rat visual cortex.

Intraocular injections of wheat germ agglutinin conjugated to horseradish peroxidase (WGA-HRP) result in anterograde transneuronal labeling of geniculocortical axon terminals in cortical area 17. In area 17 of developing rat pups, transported WGA-HRP occurs primarily in layer I and in a band that includes layer IV and deep layer III; this pattern is virtually identical to the laminar pattern of endogenous acetylcholinesterase (AChE) activity. In adult animals, transported WGA-HRP again is localized in layer I and in deep layer III and layer IV, but the endogenous AChE activity is found most prominently in deep layer IV and layer V. These results indicate that geniculocortical terminal fields are co-extensive with transient patterns of AChE activity in the developing rat, but not with the mature pattern of AChE in the adult.

Acetylcholinesterase↗